AWARD NUMBER: W81XWH-20-2-0061

TITLE: Assessing the Comparative and Longitudinal Benefits of Vascularized Composite Allotransplantation of the Hand

PRINCIPAL INVESTIGATOR: Scott Tintle, MD

CONTRACTING ORGANIZATION: Henry M. Jackson Foundation
6720 A Rockledge Dr. Suite 100
Bethesda MD 20817-1891

REPORT DATE: October 2021

TYPE OF REPORT: Annual Report

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

1. REPORT DATE	2. REPORT TYPE	3. DATES COVERED
October 2021	Annual Report	09/30/2020 to 09/29/2021

4. TITLE AND SUBTITLE

Assessing the Comparative and Longitudinal Benefits of Vascularized Composite Allotransplantation of the Hand

5a. CONTRACT NUMBER
W81XWH-20-2-0061

5b. GRANT NUMBER
RT190094

5c. PROGRAM ELEMENT NUMBER

6. AUTHOR(S)

Scott Tintle, MD
E-Mail: scott.m.tintle.mil@mail.mil

5d. PROJECT NUMBER

5e. TASK NUMBER

5f. WORK UNIT NUMBER

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)

Henry Jackson Foundation
6720 A Rockledge Dr. Suite 100
Bethesda MD 20817-1891

8. PERFORMING ORGANIZATION REPORT NUMBER

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)

U.S. Army Medical Research and Development Command
Fort Detrick, Maryland 21702-5012

10. SPONSOR/MONITOR'S ACRONYM(S)
USAMRMC

11. SPONSOR/MONITOR'S REPORT NUMBER(S)

12. DISTRIBUTION / AVAILABILITY STATEMENT

Approved for Public Release; Distribution Unlimited

13. SUPPLEMENTARY NOTES

14. ABSTRACT

Hand transplantation can restore physical functions, including movement and sensation, and qualitative evidence from our ongoing research suggests that hand transplantation can also improve well-being and quality of life (QOL). However, there are risks to receiving hand transplant surgery and patients and doctors need valid information on QOL outcomes to weigh the risks and benefits of hand transplantation. This project will address the FY19 RTRP Focus Areas to (1) define/assess the benefits or value of hand transplant, including the relative value of hand transplantation compared to other treatment options and the benefits to social participation and satisfaction, and (2) to determine how psychosocial functioning changes over time within hand transplant recipients. We will conduct qualitative interviews with participants from four different clinical groups: (1) individuals who have undergone hand transplantation, (2) individuals with severe upper-extremity injuries who have undergone limb reconstruction surgery, (3) individuals with upper-extremity amputation who use prosthetic devices, and (4) individuals with upper-extremity amputation who use osseointegrated prosthetic devices. Furthermore, we will develop a set of consensus standardized outcomes measures that can be used at all clinical sites. The overall goal of this qualitative research study is to improve the methods used for evaluating outcomes after hand transplant surgery, leading to improved clinical decision-making and improved outcomes overall. This information may help hand transplant become a more feasible option for those with hand or arm amputations, which would allow more individuals to resume productive lives as a result. To date, a comprehensive multi-site study protocol has been reviewed and approved by the University of Delaware IRB and is under review with HRPO. We have worked with participating sites to establish reliance agreements for single IRB review. Paperwork for a CRADA with Walter Reed was initiated, with the goal of engaging all sites.

15. SUBJECT TERMS

Hand Transplant, Patient reported outcomes, quality of life, vascularized composite allotransplantation, amputation, upper extremity

16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
Unclassified	Unclassified	Unclassified	Unclassified	11	19b. TELEPHONE NUMBER *(include area code)*

Standard Form 298 (Rev. 8-98)
Prescribed by ANSI Std. Z39.18

TABLE OF CONTENTS

1. INTRODUCTION

Hand transplantation can restore physical functions, including movement and sensation, and qualitative evidence from our ongoing research suggests that hand transplantation can also improve well-being and quality of life (QOL). However, there are risks to receiving hand transplant surgery and patients and doctors need valid information on QOL outcomes to weigh the risks and benefits of hand transplantation. This project will address the FY19 RTRP Focus Areas to (1) define/assess the benefits or value of hand transplant, including the relative value of hand transplantation compared to other treatment options and the benefits to social participation and satisfaction, and (2) to determine how psychosocial functioning changes over time within hand transplant recipients. We will conduct qualitative interviews with participants from four different clinical groups: (1) individuals who have undergone hand transplantation, (2) individuals with severe upper-extremity injuries who have undergone limb reconstruction surgery, (3) individuals with upper-extremity amputation who use prosthetic devices, and (4) individuals with upper-extremity amputation who use osseointegrated prosthetic devices. Furthermore, we will develop a set of consensus standardized outcomes measures that can be used at all clinical sites. The overall goal of this qualitative research study is to improve the methods used for evaluating outcomes after hand transplant surgery, leading to improved clinical decision-making and improved outcomes overall. This information may help hand transplant become a more feasible option for those with hand or arm amputations, which would allow more individuals to resume productive lives as a result.

2. KEYWORDS

Hand Transplant, Patient reported outcomes, quality of life, vascularized composite allotransplantation, amputation, upper extremity

3. ACCOMPLISHMENTS

What were the major goals of the project?

Study Specific Aims: (1) Assess the benefits of upper extremity (UE) vascularized composite allotransplantation (VCA) across emotional, social, physical, and functional domains. (1a) Understand the relative value of UE VCA compared to other treatment options (e.g., prosthetics, reconstruction, osseointegration). (1b) Document how UE VCA affects social roles, interactions, and functioning, including sense of self and wholeness. (2) Explore how psychosocial functioning and QOL change over time for UE VCA recipients. (3) Develop a consensus set of psychosocial and QOL outcome variables that can be assessed longitudinally across VCA clinical centers.

Statement of Work – Tasks and Subtasks	**% Complete**
Major Task 1: Prepare Regulatory and Administrative Documents for Data Collection	
Subtask 1.1: Finalize study procedures, consent form(s), and human subject protocol	100
Subtask 1.2: Coordinate IRB protocol submission at UD	100
Subtask 1.3: Coordinate IRB protocol submission at WR	50
Subtask 1.4: Coordinate IRB protocol submissions at other recruitment sites	50
Subtask 1.5: Coordinate protocol submission to HRPO at UD	50
Subtask 1.6: Coordinate protocol submission to HRPO at WR	
Subtask 1.7: Coordinate protocol submission to HRPO at other sites, as necessary	
Subtask 1.8: Coordinate administrative approvals (e.g., Data Sharing Agreements) among all sites, as necessary	20
Major Task 2: Conduct Baseline Interviews with Participants (n = 100)	

Subtask 2.1: Develop data collection platform (i.e., REDCap) and finalize interview procedures	
Subtask 2.2: Recruit and screen participants	
Subtask 2.3: Enroll and interview participants	
Major Task 3: Analyze Data from Baseline Interviews	
Subtask 3.1: Conduct thematic qualitative analyses	
Subtask 3.2: Conduct descriptive analyses of data from baseline interviews	
Subtask 3.3: Evaluate and summarize results from Aim 1 analyses	
Major Task 4: Conduct Longitudinal Interviews with Participants (n = 100)	
Subtask 4.1: Develop longitudinal data collection platform and finalize interview procedures	
Subtask 4.2: Re-contact and interview participants from Aim 1 data collection	
Major Task 5: Analyze Data from Longitudinal Interviews	
Subtask 5.1: Conduct thematic qualitative analysis from longitudinal interviews	
Subtask 5.2: Conduct descriptive analysis of data from longitudinal interviews	
Subtask 5.3: Evaluate and summarize results from Aim 2 analyses	
Major Task 6: Identify and Disseminate a Set of Recommended Outcome Variables for VCA of the Hand	
Subtask 6.1: Develop a proposed set of outcome variables based on results from prior research and the Aim 1 results	
Subtask 6.2: Share recommendations with partnering VCA collaborators and gather feedback	
Subtask 6.3: Revise recommendations based on feedback	
Subtask 6.4: Summarize recommendations and prepare for dissemination to VCA clinical sites	

What was accomplished under these goals?

Major Task 1: Prepare Regulatory and Administrative Documentation

During year 1, a comprehensive multi-site study protocol has been reviewed and approved by the University of Delaware IRB and is under review with HRPO. Following the UD IRB's request to confirm that all sites were amenable to a single IRB model for this project, in light of the current DoD guidelines, we have approached all of the involved recruiting sites to gather information on the opportunity for a reliance agreement with the University of Delaware IRB. All sites have confirmed their willingness to have UD be the IRB of record. We have held meetings individually with Walter Reed, Johns Hopkins, UCLA, Brigham and Women's, and Massachusetts General teams to review each site's and UD's regulatory and administrative documentation requirements, and created follow-up plans for each site. The University of Pennsylvania and the University of Louisville teams are planning to participate in the activities for this grant by amending their existing IRB protocols, which were established for our initial grant (W81XWH-18-2-0068). Staff at Walter Reed have begun the paperwork for a cooperative research and development agreement (CRADA) that will cover all involved sites, and will include the necessary data sharing agreement(s). All subawards have been established with participating sites. Since we have not yet received full regulatory approval, minimal grant funds have been used during this period

What opportunities for training and professional development has the project provided?

Nothing to report

How were the results disseminated to communities of interest?

Nothing to report

What do you plan to do during the next reporting period to accomplish the goals?

In year 2 of this project, we will obtain HRPO approvals for conducting individual patient participant interviews at the University of Delaware, obtain IRB and HRPO approvals for recruiting patient participants from the involved sites, finalize site-specific agreements for data sharing and other administrative concerns, develop the data collection procedures and platform, train data collectors, and initiate the patient participant interviews.

4. IMPACT

What was the impact on the development of the principal discipline(s) of the project?

We have brought together many of the clinical sites involved in hand transplantation in the United States by forming the TORCH Consortium (Transplant Outcomes Research Collaborative for the Hand). Forming this consortium will have a major impact on the field because it will allow for improved synchronization of efforts for standardizing outcomes measures for hand transplantation research and clinical care. This consortium will also allow our research team to recruit and enroll many the available hand transplant participants in the U.S., as well as osseointegration participants, both of which are relatively small populations nationwide.

What was the impact on other disciplines?

Nothing to Report

What was the impact on technology transfer?

Nothing to Report

What was the impact on society beyond science and technology?

Nothing to Report

5. CHANGES/PROBLEMS

Changes in approach and reasons for change

Nothing to Report

Actual or anticipated problems or delays and actions or plans to resolve them

Regulatory and administrative approvals have taken longer than anticipated. To address this, we have delayed expenditures to assure funds are available to accomplish all project goals. We are working closely with representatives from all sites to establish single IRB reliance agreements as well as a CRADA that will cover all sites.

Changes that had a significant impact on expenditures

The delays in regulatory approvals have caused corresponding delays in spending for this project. However, we anticipate that the effect of this will be neutral on the budget over the life of the project.

Significant changes in use or care of human subjects.

Nothing to Report

Significant changes in use or care of vertebrate animals.

Nothing to Report

Significant changes in use of biohazards and/or select agents.

Nothing to Report

6. PRODUCTS

Publications, conference papers, and presentations

Journal publications. Nothing to Report

Books or other non-periodical, one-time publications. Nothing to Report

Other publications, conference papers, and presentations. Nothing to Report

Website(s) or other Internet site(s)

Nothing to Report

Technologies or techniques

Nothing to Report

Inventions, patent applications, and/or licenses

Nothing to Report

Other Products

Nothing to Report

7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS

What individuals have worked on the project?

Walter Reed National Military Medical Center (WR)

Name:	**CDR Scott Tintle, MD**
Project Role:	Initiating PI at WR
ORCID ID:	0000-0003-0887-7600
Nearest person month worked:	1
Contribution to project:	CDR Tintle oversaw all aspects of the project-related activities, including teleconferences and initial planning activities.

Name: **Christopher L. Dearth, PhD**
Project Role: Co-Investigator at WR
ORCID ID: 0000-0003-3701-0950
Nearest person month worked: 1
Contribution to project: Dr. Dearth participated in project coordination activities.
Name: **Toby Perkins**
Project Role: Regulatory at WR
ORCID ID: none
Nearest person month worked: 1
Contribution to project: Ms. Perkins has been working on the IRB/CRADA/DSA.

University of Delaware (UD)
Name: **David Tulsky, PhD**
Project Role: Collaborating PI at UD
ORCID ID: 0000-0002-4335-4509
Nearest person month worked: 1
Contribution to Project: Dr. Tulsky oversaw all aspects of the project-related activities at UD, including planning teleconferences and creation of IRB protocol at UD.
Name: **Jerry Slotkin, PhD**
Project Role: Co-Investigator at UD
ORCID ID: 0000-0001-8199-3056
Nearest person month worked: 1
Contribution to Project: Dr. Slotkin participated in planning teleconferences, UD IRB protocol creation, and CRADA development.
Name: **Callie Tyner, PhD**
Project Role: Co-Investigator at UD
ORCID ID: 0000-0003-2945-392X
Nearest person month worked: 1
Contribution to Project: Dr. Tyner participated in planning teleconferences, led the UD IRB protocol development, and assisted with CRADA development.
Name: **Emily Forth, BA**
Project Role: Research Assistant at UD
ORCID ID: none
Nearest person month worked: 1
Contribution to Project: Ms. Forth contributed to IRB protocol development.

Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?

Walter Reed/ Henry Jackson Foundation

Scott Tintle, MD

New funding

1. Title: Oxandrolone Supplementation in Trauma: The Post-Injury Trial
   Funding Agency: USAMRAA/ CDMRP
   Project dates: 9/30/2021-9/29/2024
   Effort: 0.60
   Description: To compare Oxandrolone therapy and standard rehabilitation in patients

who have suffered high energy fractures. The primary outcome is total quadriceps mass measured at one year after the injury Overlap: none

University of Delaware (UD)

David Tulsky, Ph.D.

New funding:

2. Title: Online Symptom-Monitoring/Self-Management for Pandemic-Related Emotional Distress (ACCEL)
   Funding Agency: NIH/NIGMS
   Project dates: 7/1/2021-6/30/2022
   Effort: 0.60 academic
   Description: To adapt an existing, web-based "ehealth" symptom-monitoring/self-management system, iManage, to the needs of the general population in the wake of the COVID-19 crisis. Overlap: none
3. Title: Relations between motor social and social communication impairments as well as repetitive behavior severity in children with autism spectrum disorder (ASD)
   Funding Agency: NIH
   Project dates: 6/1/2021-3/31/2024
   Effort: 0.24 academic
   Description: We will determine the risk for motor impairment and how that changes with increasing social communication impairment, repetitive behavior severity, comorbidities, and levels of impairment using parent report measures. Overlap: none

Previous funding:

- Development of Psychosocial Symptom Monitoring and Self-Management System for individuals with SCI (CNF), ended 2/28/2021
- Stakeholder Determination of Patient-Reported Outcomes for Adults with Communication Disorders (NIH/NIGMS), ended 11/30/2020
- Women's Health & Disability: Building a Clinically Relevant Outcome Measure (Univ Mich/NIH), ended 5/31/2021

Jerry Slotkin, Ph.D.

New funding:

1. Title: Online Symptom-Monitoring/Self-Management for Pandemic-Related Emotional Distress (ACCEL)
   Funding Agency: NIH/NIGMS
   Project dates: 7/1/2021-6/30/2022
   Effort: 0.24 calendar
   Description: To adapt an existing, web-based "ehealth" symptom-monitoring/self-management system, iManage, to the needs of the general population in the wake of the COVID-19 crisis.
   Overlap: none

Previous funding:

- Development of Psychosocial Symptom Monitoring and Self-Management System for individuals with SCI (CNF), ended 2/28/2021

Callie Tyner, Ph.D.

Nothing to report

What other organizations were involved as partners?

Nothing to Report

8. SPECIAL REPORTING REQUIREMENTS

Collaborative Awards

n/a

Quad Charts

See Appendix A

9. APPENDICES

See Appendix A for Quad Chart: following page

Appendix A: Quad Chart. Assessing the Comparative and Longitudinal Benefits of Vascularized Composite Allotransplantation of the Hand

Log Number: RT190094; Award Number: W81XWH-20-2-0061

PI: Scot Tintle, MD **Organization:** Henry M. Jackson Foundation(HJF) **Award Amount:** $ 494,635

Specific Aims

Aim 1: Assess the benefits of upper extremity (UE) vascularized composite allotransplantation (VCA) across emotional, social, physical, and functional domains. (1a) Understand the relative value of UE VCA compared to other treatment options (e.g., prosthetics, reconstruction, osseointegration). (1b) Document how UE VCA affects social roles, interactions, and functioning, including sense of self and wholeness.

Aim 2: Explore how psychosocial functioning and QOL change over time for UE VCA recipients.

Aim 3: Develop a consensus set of psychosocial and QOL outcome variables that can be assessed longitudinally across VCA clinical centers.

Approach

These aims will be accomplished by using state-of-the-art qualitative and quantitative methods, employing both open-ended interviews and population-specific patient-reported outcomes (PRO) measurement items to assess quality of life (QOL) in four clinical groups: individuals who have undergone hand transplantation (n = 25), those with limb preservation or reconstruction (n = 25), traditional prosthesis users (n = 25, including myoelectric and body-powered), and those with osseointegrated prosthetics (n = 25).

Qualitative interviews will generate ***comparative*** and ***longitudinal*** information on psychosocial and QOL outcomes.



Results will lead to recommended **common data elements** for evaluating and monitoring outcomes across VCA clinical centers.

Accomplishments: During Year 1, we worked on the regulatory and administrative documentation to launch the study. The study protocol was approved by the University of Delaware IRB and is under review with HRPO. We worked with participating sites to establish reliance agreements. Paperwork for a CRADA with Walter Reed was initiated, with the goal of engaging all sites.

Timeline and Cost

Activities and Milestones	Year 1	Year 2	Year 3
Finalize study procedures and protocol	■		
Coordinate regulatory and administrative approvals	■	■	
Develop data collection platform and finalize interview procedures	■	■	
Recruit participants (n = 100) and complete baseline interviews	■	■	
Analyze qualitative baseline interview data and summarize Aim 1 results		■	■
Develop longitudinal data collection platform and interview procedures		■	
Re-contact participants (n = 100) and complete longitudinal interviews		■	■
Analyze qualitative longitudinal interviews and summarize Aim 2 results			■
Develop proposed set of consensus outcome measures			■
Share recommendations with VCA collaborators and gather feedback			■
Revise recommendations based on feedback			■
Summarize Aim 3 recommendations and disseminate to VCA clinical sites			■

Updated: 25-Oct-2021

Goals/Milestones

Year 1 Goals: Regulatory and Administrative Approvals

- ☐ IRB **(APPROVED);**HRPO approval pending for at U. of Delaware- **in progress**
- ☐ Milestone: IRB and HRPO approval obtained at Walter Reed
- ☐ Milestone: IRB, HRPO & administrative approvals obtained at participating sites

Year 2 Goals: Complete Baseline Interviews & Analyze Aim 1 Results

- ☐ Milestone: Participant interviews (n = 100) completed
- ☐ Milestone: Analyses for Aim 1 completed

Year 3 Goals: Complete Longitudinal Interviews & Analyze Aim 2 Results; Develop and Finalize Recommended Common Data Elements

- ☐ Milestone: Longitudinal interviews (n = 100) completed
- ☐ Milestone: Analyses for Aim 2 completed
- ☐ Milestone: Final recommendations summarized and shared

Comments/Challenges/Issues/Concerns

Some regulatory delays due to pandemic and gaining site reliance for unified IRB. Expenditures delayed to assure funds are available to accomplish all goals.